Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
Price : $35 *
At a glance
- Drugs ALD 301 (Primary)
- Indications Intermittent claudication; Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms PACE
- 10 Apr 2017 Status changed from active, no longer recruiting to completed.
- 11 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 03 Nov 2015 Planned End Date changed from 1 Jul 2016 to 1 Mar 2017, according to ClinicalTrials.gov record.